tiprankstipranks
Santen Pharmaceutical Co Ltd (MX:4536N)
:4536N
Mexico Market
4536N
Santen Pharmaceutical Co
RESEARCH TOOLSreports

Santen Pharmaceutical Co (4536N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

4536N Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Santen
Pharmaceutical Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4536N Stock 12 Month Forecast

Average Price Target

$261.43
▲(4.57% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Santen Pharmaceutical Co in the last 3 months. The average price target is $261.43 with a high forecast of $261.43 and a low forecast of $261.43. The average price target represents a 4.57% change from the last price of $250.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"244":"$244","253":"$253","262":"$262","248.5":"$248.5","257.5":"$257.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":261.428034,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$261.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":261.428034,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$261.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":261.428034,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$261.43</span>\n  </div></div>","useHTML":true}}],"tickPositions":[244,248.5,253,257.5,262],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Aug<br/>2025","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250,250.87907953846155,251.75815907692308,252.63723861538463,253.51631815384616,254.3953976923077,255.27447723076924,256.15355676923076,257.0326363076923,257.91171584615387,258.7907953846154,259.6698749230769,260.5489544615385,{"y":261.428034,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250,250.87907953846155,251.75815907692308,252.63723861538463,253.51631815384616,254.3953976923077,255.27447723076924,256.15355676923076,257.0326363076923,257.91171584615387,258.7907953846154,259.6698749230769,260.5489544615385,{"y":261.428034,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250,250.87907953846155,251.75815907692308,252.63723861538463,253.51631815384616,254.3953976923077,255.27447723076924,256.15355676923076,257.0326363076923,257.91171584615387,258.7907953846154,259.6698749230769,260.5489544615385,{"y":261.428034,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":245.099,"date":1627776000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":245.099,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.099,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.099,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":247.656,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":247.656,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":247.656,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$261.43Average Price Target$261.43Lowest Price Target$261.43
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on MX:4536N
Unknown Analyst
UBS
Not Ranked
UBS
$245.42→$261.43
Buy
4.57%
Upside
Reiterated
07/14/26
Santen Pharmaceutical Co (SNPHF) Gets a Buy from UBS
Goldman Sachs Analyst forecast on MX:4536N
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$261.43→$234.75
Buy
-6.10%
Downside
Reiterated
10/10/25
Santen Pharmaceutical Co (SNPHF) Receives a Buy from Goldman Sachs
Citi Analyst forecast on MX:4536N
Hidemaru Yamaguchi
Citi
Citi
$266.76→$277.43
Buy
10.97%
Upside
Reiterated
08/22/25
Citi Sticks to Its Buy Rating for Santen Pharmaceutical Co (SNPHF)
Jefferies Analyst forecast on MX:4536N
Stephen Barker
Jefferies
Jefferies
$181.4
Hold
-27.44%
Downside
Downgraded
08/08/25
Santen Pharmaceutical Co (SNPHF) was downgraded to a Hold Rating at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on MX:4536N
Unknown Analyst
UBS
Not Ranked
UBS
$245.42→$261.43
Buy
4.57%
Upside
Reiterated
07/14/26
Santen Pharmaceutical Co (SNPHF) Gets a Buy from UBS
Goldman Sachs Analyst forecast on MX:4536N
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$261.43→$234.75
Buy
-6.10%
Downside
Reiterated
10/10/25
Santen Pharmaceutical Co (SNPHF) Receives a Buy from Goldman Sachs
Citi Analyst forecast on MX:4536N
Hidemaru Yamaguchi
Citi
Citi
$266.76→$277.43
Buy
10.97%
Upside
Reiterated
08/22/25
Citi Sticks to Its Buy Rating for Santen Pharmaceutical Co (SNPHF)
Jefferies Analyst forecast on MX:4536N
Stephen Barker
Jefferies
Jefferies
$181.4
Hold
-27.44%
Downside
Downgraded
08/08/25
Santen Pharmaceutical Co (SNPHF) was downgraded to a Hold Rating at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Santen Pharmaceutical Co

3 Months
DeepSeek Drug Manufacturers - GeneralTipRanks - DeepSeek
Success Rate
1/2 ratings generated profit
50%
Average Return
+7.15%
reiterated a buy rating 16 days ago
Copying DeepSeek Drug Manufacturers - General's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +7.15% per trade.
1 Year
DeepSeek Drug Manufacturers - GeneralTipRanks - DeepSeek
Success Rate
1/2 ratings generated profit
50%
Average Return
+7.15%
reiterated a buy rating 16 days ago
Copying DeepSeek Drug Manufacturers - General's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.15% per trade.
2 Years
DeepSeek Drug Manufacturers - GeneralTipRanks - DeepSeek
Success Rate
1/2 ratings generated profit
50%
Average Return
+7.15%
reiterated a buy rating 16 days ago
Copying DeepSeek Drug Manufacturers - General's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +7.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4536N Analyst Recommendation Trends

Rating
Dec 25
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
14
21
24
24
52
Buy
1
1
0
0
0
Hold
4
7
11
11
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
29
35
35
66
In the current month, 4536N has received 52 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 4536N average Analyst price target in the past 3 months is 261.43.
Each month's total comprises the sum of three months' worth of ratings.

4536N Financial Forecast

4536N Earnings Forecast

Next quarter’s earnings estimate for 4536N is $2.34 with a range of $2.21 to $2.59. The previous quarter’s EPS was $5.28. 4536N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 4536N has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4536N is $2.34 with a range of $2.21 to $2.59. The previous quarter’s EPS was $5.28. 4536N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 4536N has Performed in-line its overall industry.

4536N Sales Forecast

Next quarter’s sales forecast for 4536N is $7.76B with a range of $7.45B to $8.02B. The previous quarter’s sales results were $8.91B. 4536N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year 4536N has Performed in-line its overall industry.
Next quarter’s sales forecast for 4536N is $7.76B with a range of $7.45B to $8.02B. The previous quarter’s sales results were $8.91B. 4536N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year 4536N has Performed in-line its overall industry.

4536N Stock Forecast FAQ

What is MX:4536N’s average 12-month price target, according to analysts?
Based on analyst ratings, Santen Pharmaceutical Co Ltd’s 12-month average price target is 261.43.
    What is MX:4536N’s upside potential, based on the analysts’ average price target?
    Santen Pharmaceutical Co Ltd has 4.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Santen Pharmaceutical Co Ltd a Buy, Sell or Hold?
          Santen Pharmaceutical Co Ltd has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Santen Pharmaceutical Co Ltd’s share price target?
            The average share price target for Santen Pharmaceutical Co Ltd is 261.43. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $261.43 ,and the lowest forecast is $261.43. The average share price target represents 4.57% Increase from the current price of $250.
              What do analysts say about Santen Pharmaceutical Co Ltd?
              Santen Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Santen Pharmaceutical Co Ltd?
                To buy shares of MX:4536N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.